SDMHF — Sartorius Stedim Biotech S.A./ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 1794363 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-07-23
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 761,500,000 | 345,400,000 | 149,300,000 | 88,100,000 | 8,189,800,000 | 521,200,000 | 4,046,800,000 |
| Dec 2025 | 772,200,000 | 316,900,000 | 134,400,000 | 47,300,000 | 7,984,000,000 | 426,100,000 | 3,857,900,000 |
| Jun 2025 | 745,000,000 | 344,700,000 | 129,000,000 | 68,500,000 | 8,312,400,000 | 699,300,000 | 4,273,000,000 |
| Mar 2025 | 744,600,000 | 356,300,000 | 141,300,000 | 85,600,000 | 8,303,500,000 | 707,600,000 | 4,295,500,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$684,500,000
Investing CF
$-330,600,000
Financing CF
$-107,200,000
CapEx
$-327,900,000
Dividends Paid
$0
Buybacks
$-3,200,000
EPS Diluted TTM
$2.74
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$2,664,900,000
Inventory
$714,700,000
Receivables
—
ST Investments
$26,200,000
EBIT TTM
$539,400,000
Pretax Income TTM
$404,900,000
Interest Exp TTM
$134,500,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,984,399,872
EBITDA
$789,800,000
Free Cash Flow
$256,062,496
Enterprise Value
$20,961,069,056
Total Cash
$521,200,000
Total Debt
$2,614,599,936
Shares Out
97,277,797
Trailing EPS
$3.21
Book Value
$49.60
ROE
6.6%
ROA
4.1%
Div Yield
0.41%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,967,500,000 | 539,400,000 | 265,600,000 | 7,984,000,000 | 3,857,900,000 | — | 692,200,000 |
| Dec 2024 | 2,780,000,000 | 397,600,000 | 175,100,000 | 8,256,400,000 | 4,232,600,000 | — | 815,100,000 |
| Dec 2023 | 2,775,500,000 | 471,200,000 | 310,300,000 | 7,730,100,000 | 5,056,300,000 | — | 746,400,000 |
| Dec 2022 | 3,492,700,000 | 1,055,000,000 | 876,100,000 | 5,065,400,000 | 2,551,200,000 | — | 612,300,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF TRUST | $688.88B | $750.59 | — |
| KLAC | KLA CORP | $262.74B | $2011.39 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $235.62B | $250.69 | — |
| KXIAY | Kioxia Holdings Corporation/ADR | $231.81B | $42.45 | — |
| SMEGF | Siemens Energy AG/ADR | $180.38B | $212.00 | — |
News headlines (Yahoo Finance, 1h cache)
European Stocks Possibly Trading Below Estimated Value May 2026
2026-05-06 05:38 · Yahoo
[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation,
2026-02-11 08:30 · Yahoo
Sartorius Stedim Biotech SA (SDMHF) Q4 2025 Earnings Call Highlights: Strong Profit Growth and ...
2026-02-03 19:01 · Yahoo
Discover 3 European Stocks Believed To Be Trading Below Intrinsic Value
2025-10-02 05:37 · Yahoo
European Hidden Value Stocks That Might Be Priced Below Intrinsic Estimates
2025-09-02 05:37 · Yahoo
Sartorius to invest $3m for minority share in biotech start-up Nanotein
2025-08-12 10:54 · Yahoo
Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing
2025-08-11 13:00 · Yahoo
3 European Stocks Estimated At Up To 41.3% Discount To Intrinsic Value
2025-07-30 05:37 · Yahoo
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
2025-07-29 14:14 · Yahoo
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platform
2025-07-09 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.